Lowest Price Guaranteed From USD 1,699
Published
July 2013
Pages
145
View Count
9164
Example Insights
An updated edition is available at the following link
Report Description
Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics. These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology. This class of biologics is attracting the attention of drug developers, with several large and small companies entering the market through collaboration and licensing agreements with technology providers.
The ADC market is still in its infancy. So far, three ADCs have received market approval. However, the first ADC, Mylotarg, was withdrawn from the market by its developer Pfizer. As such, there are only two marketed drugs in 2013. During the journey of these molecules from pipeline to the market, there have been some regulatory and commercial setbacks. However, the recent launch of Roche’s much awaited Kadcyla (T-DM1) has provided a positive outlook to the future of the market.
The pipeline is rich, though not many molecules are in the pivotal trial stage yet. It will be a few years before the market picks up pace with the launch of several pipeline drugs. Majority of the ADCs currently under development are for oncological indications, driven by the availability of monoclonal antibodies targeting various types of cancer. However, some drug developers are now also looking outside the oncology domain to develop ADCs, though, such ADCs are only in preclinical or discovery stage of development.
Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. ImmunoGen and Seattle Genetics are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, as the market matures, we expect to see more co-development agreements in the future.
Amongst other things, this report provides a detailed overview of the most promising pipeline ADCs, with our analysis of the future of eight ADCs. Furthermore, it also includes our view of the market for contract manufacturing of ADCs. We have identified contract manufacturing organisations with capabilities in various stages of ADC development and manufacturing.
Scope of the Report
The 'Antibody Drug Conjugates Market, 2012-2023' report provides an extensive study of the emerging market of antibody drug conjugates (ADC). This emerging field of therapeutics is still in its infancy, with not many marketed products in 2013. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics and the need for this new class of medicine.
One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analysing
The base year for the report is 2012, with actual sales data presented for marketed ADCs during the year and the global ADC market. The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2019 - 2023, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of eight marketed and pipeline ADCs, which together comprise our total ADC market.
Owing to niche nature of the market, with most products in the pipeline, we provide three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios are considered for the forecasting of each of the eight drugs constituting the ADC market.
All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides a general introduction to antibody drug conjugates. We discuss in detail the components of an ADC, as well as the advantages of ADC as a therapeutic drug over traditional treatments.
Chapter 3 provides an overview of the ADC market with respect to marketed and pipeline drugs, and companies active in the field. It includes analysis of the ADC market from the viewpoint of the indications targeted, most commonly used linkers and cytotoxic drugs through analysis of the extensive ADC pipeline.
Chapter 4 analyses the current and future state of the global ADC market. Presented is the market data for base year 2012 and our forecasts for 2013 - 2023. The chapter includes, in detail, our sales forecast for two marketed and six pipeline drugs. The latter is based on discussion of several parameters including status of development, expected approval and competition amongst others.
Chapter 5 reviews the challenges of manufacturing an ADC and compares the capabilities of some contract manufacturers in the market. We present profiles of three leading contract manufactures with capabilities related to ADC manufacturing.
Chapter 6 explores in brief some key pipeline ADC drugs not covered in the market chapter. We have included a discussion on key technological developments likely to support the growth of the ADC market. Furthermore, we discuss the partnership models existing in the ADC market.
Chapter 7 includes profiles of the key companies in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent developments.
Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.
Chapter 9 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 10 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
1. EXECUTIVE SUMMARY
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1.4. Key Highlights
1.4.1. Adcetris was the Sole Participant in the Market in 2012
1.4.2. Approval of Kadcyla Likely to Strengthen ADC Market
1.4.3. Oncology Dominates the Field of ADC
1.4.4. Seattle Genetics and ImmunoGen are the Leading Technology Providers
1.4.5. Technology Licensing is the Preferred Model for ADC Development
2. INTRODUCTION
2.1. Chapter Overview
2.2. The Traditional Treatments: Naked Antibody and Cytotoxins
2.2.1. Naked Antibodies
2.2.1.1. How Monoclonal Antibody Therapy Works
2.2.2. Cytotoxins
2.3. Conjugated or Armed Antibodies
2.4. The Revolutionary Technology: ADCs
2.5. Advantages of ADC over Traditional Therapeutics
2.6. Parts of an ADC
2.6.1. Antibody
2.6.2. Cytotoxin
2.6.3. Linker: Function and Types
3. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND
3.1. Chapter Overview
3.2. Kadcyla Becomes Third ADCs to Reach Market
3.2.1. Mylotarg (Pfizer)
3.2.1.1. Mechanism of Action
3.2.1.2. Approval and Discontinuation of Mylotarg in the US
3.2.1.3. Reasons for Poor Clinical Benefits of Mylotarg
3.2.2. Adcetris (Seattle Genetics/Takeda Oncology Company)
3.2.3. Kadcyla (Roche/Genentech)
3.3. Companies Active in the ADC Market
3.3.1. Large Pharmaceutical Companies Taking Interest
3.4. Companies Providing ADC Technology
3.5. Role of Venture Capitalists
3.6. Analysis of the Development Pipeline
3.6.1. Limited Number of Molecules in Late Stage Development
3.6.2. Cancer is the Leading Indication, with ADCs Against Blood Cancer Dominating
3.6.3. Auristatins are the Most Popular Toxin Being Studied
3.6.4. ADC Market by Type of Linker
4. ADC MARKET, 2012 - 2023
4.1. Chapter Overview
4.2. ADC Market, 2012
4.2.1. Adcetris was the Sole Participant in the Market in 2012
4.3. Overall ADC Market Forecast, 2013-2023
4.3.1. Scope and Limitations
4.3.2. Assumptions for Market Forecast
4.3.3. Overall ADC Market Forecast: Short-Midterm, 2013-2018
4.3.4. Overall ADC Market Forecast: Long Term, 2019-2023
4.4. Adcetris (Seattle Genetics / Millennium)
4.4.1. Mechanism of Action
4.4.2. The Cost of Treatment with Adcetris and Reimbursement
4.4.3. Factors Supporting the High Price
4.4.4. Adcetris Sales, 2011-Q1 2013
4.4.5. Strategies for Market Expansion
4.4.6. Adcetris Sales Forecast: Short-Mid Term, 2013-2018
4.4.7. Adcetris Sales Forecast: Long Term, 2019-2023
4.5. Kadcyla / T-DM1 (Genentech / Roche)
4.5.1. The Drug Specifications
4.5.2. Launch and Pricing
4.5.3. Roche’s Survival Kit
4.5.4. Long Route to Approval
4.5.5. Kadcyla Sales
4.5.6. Current State of Development: Indications and Timeline
4.5.7. Kadcyla Sales Forecast, 2013-2018
4.5.8. Kadcyla Sales Forecast: Long Term, 2019-2023
4.6. Inotuzumab Ozogamicin/CMC-544 (Pfizer)
4.6.1. The Drug Specifications
4.6.2. Current Development Status
4.6.3. Inotuzumab Ozogamicin / CMC-544 Sales Forecast, 2013-2018
4.6.4. Inotuzumab Ozogamicin / CMC-544 Sales Forecast: Long Term, 2019-2023
4.7. Glembatumumab Vedotin / CDX-011 (Celldex Therapeutics)
4.7.1. The Drug Specifications
4.7.2. Clinical Development
4.7.2.1. EMERGE Trial
4.7.3. CDX-011 Sales Forecast, 2013-2018
4.7.4. CDX-011 Sales Forecast: Long Term, 2019-2023
4.8. Lorvotuzumab Mertansine / IMGN901 (ImmunoGen)
4.8.1. Drug Specifications
4.8.2. Clinical Development
4.8.3. IMGN901 Sales Forecast: Short-Midterm, 2013-2018
4.8.4. IMGN901 Sales Forecast: Long Term, 2013-2018
4.9. SAR3419 (Sanofi Aventis)
4.9.1. The Drug Specifications
4.9.2. Structure, Administration and Dosage
4.9.3. Current State of Development
4.9.4. Competition for SAR3419
4.9.5. SAR3419 Sales Forecast: Short-Midterm, 2013-2018
4.9.6. SAR3419 Sales Forecast: Long Term, 2019-2023
4.10. BT-062 (Biotest)
4.10.1. Drug Specifications
4.10.2. Clinical Development
4.10.3. Market Opportunity and Sales Forecast
4.10.4. BT-062 Sales Forecast: Long Term, 2019-2023
4.11. PSMA-ADC (Progenics)
4.11.1. Drug Specifications
4.11.2. PSMA ADC Development for Prostate Cancer
4.11.3. Competition for PSMA ADC
4.11.4. PSMA ADC Sales Forecast, 2019-2023
5. Manufacturing of ADCs
5.1. Chapter Overview
5.2. Steps Involved in Manufacturing an ADC
5.3. Challenges Facing the ADC Manufacturers
5.4. Presence of Contract Manufacturers
5.4.1. Linkers
5.4.2. Cytotoxins
5.4.3. Conjugation
5.5. Leading ADC Contract Manufacturers
5.5.1. SAFC
5.5.2. Piramal Healthcare
5.5.3. Lonza
5.6. CMOs Investing in ADC Capabilities
5.7. Contract Manufacturers Collaborating to Provide ADC Capabilities
6. PIPELINE AND MARKET DEVELOPMENTS
6.1. Chapter Overview
6.2. Pipeline Drug Profile
6.2.1. RG7593 and RG7596 (Roche/Genentech)
6.2.2. BAY 94-9343 (Bayer Pharma)
6.3. Recent Partnerships
6.3.1. Partnership Models
6.4. Technological Developments
6.4.1. Emerging Cytotoxins/Payload
6.4.2. Linker Technologies
6.4.3. Site-Specific Conjugation Technology
6.4.4. Use of Antibody Fragments in Place of Whole Antibody
7. PROFILES OF LEADING COMPANIES
7.1. Chapter Overview
7.2. ImmunoGen
7.2.1. Targeted Antibody Payload (TAP) Technology
7.2.1.1. Linker Technology
7.2.2. Marketed and Pipeline Products
7.2.2.1. Marketed ADCs
7.2.2.2. Pipeline ADCs
7.2.3. Business Model
7.2.3.1. Types of Agreements
7.2.4. In-House Manufacturing Capabilities
7.2.5. Financial Performance
7.3. Seattle Genetics
7.3.1. ADC Technology
7.3.2. Exploring New Technologies
7.3.2.1. Novel Cytotoxins
7.3.2.2. Site-Specific Conjugation Technology
7.3.3. Business Model
7.3.3.1. Types of Agreements and Current Partners
7.3.4. Marketed and Pipeline Products
7.3.4.1. Marketed ADCs
7.3.4.2. Pipeline ADCs
7.3.5. Financial Performance
7.4. Immunomedics
7.4.1. Marketed and Pipeline Products
7.4.2. Financial Performance
7.5. Spirogen
7.5.1. Pyrrolobenzodiazepines (PBDs) Technology
7.5.2. ADC Development and Collaborations
7.6. Pfizer
7.6.1. Marketed and Pipeline Products
7.6.2. Collaboration with Seattle Genetics
7.6.3. Financial Performance
7.7. Roche/Genentech
7.7.1. Evaluating Technology from ImmunoGen and Seattle Genetics
7.7.2. Development Pipeline: Nine Molecules in Clinical Development
7.7.3. Financial Performance
8. SWOT Analysis
8.1. Strengths
8.1.1. Lifecycle Management Tool
8.1.2. Presence of Most Large Pharmaceutical Companies
8.2. Weaknesses
8.2.1. Limited Number of Technology Providers
8.2.2. Final ADCs are Often Heterogeneous
8.2.3. Association with Multiple CMOs
8.3. Opportunities
8.3.1. Contract Manufacturing of ADC Components and Conjugation
8.3.2. Site-Specific Conjugation
8.4. Threats
8.4.1. Lack of Clear Regulatory Guidelines
8.4.2. High Failure Rate May Lessen the Confidence in Technology
8.4.3. Competing Technology
9. CONCLUSIONS
9.1. ADC: Expanding the Pipeline of Biologics
9.2. Market is in its Infancy, with Huge Potential for Growth
9.3. An Attractive Market for Large Pharmaceutical Companies
9.4. Concluding Remarks
10. APPENDIX 1: TABLES
11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
Figure 2.1 Parts of Antibody Drug Conjugate
Figure 3.1 Companies Active in the ADC Market: Number of Molecules in Development
Figure 3.2 ADCs in Clinical Development: Share (%) by Phase of Development
Figure 3.3 ADCs in Clinical Development: Share (%) by Cytotoxin Used
Figure 4.1 ADC Market (USD MM), Short-Midterm Forecast: 2012-2018 (Base Scenario)
Figure 4.2 ADC Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Figure 4.3 Adcetris Quarterly Sales, 2011-2013 (USD MM)
Figure 4.4 Adcetris Market (USD MM), Short-Midterm Forecast: 2013-2018 (Base Scenario)
Figure 4.5 Adcetris Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Figure 4.6 Kadcyla / T-DM1 Market (USD MM), Short-Midterm Forecast: 2013-2018 (Base Scenario)
Figure 4.7 Kadcyla / T-DM1 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Figure 4.8 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Short-Midterm Forecast: 2015-2018 (Base Scenario)
Figure 4.9 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Figure 4.10 Glembatumumab Vedotin / CDX-011 Market (USD MM), Short-Midterm Forecast: 2016-2018 (Base Scenario)
Figure 4.11 Glembatumumab Vedotin / CDX-011 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Figure 4.12 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Figure 4.13 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Figure 4.14 SAR3419 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Figure 4.15 SAR3419 Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Figure 4.16 BT-062 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Figure 4.17 BT-062 Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Figure 4.18 PSMA ADC Sales Forecast (USD MM), 2019-2023 (Base Scenario)
Figure 7.1 Seattle Genetics: Sales Performance (USD MM), 2011 and 2012
Figure 7.2 Pfizer Sales Performance (USD MM), 2011 and 2012
Figure 7.3 Roche Group Sales Performance (USD MM), 2011 and 2012
Figure 7.4 Roche Group HER2 Franchise Sales Performance (USD MM), 2012 and 1Q 2013
Figure 9.1 ADC Market Forecast (USD MM), 2012, 2018 and 2023
Table 2.1 Some Commonly Used Cytotoxins for ADC Therapeutics
Table 3.1 Approval History of Mylotarg
Table 3.2 ADC Molecules in Clinical Development, 2013
Table 3.3 ADC Molecules in Preclinical Development, 2013
Table 3.4 Linkers Used for Some ADCs, 2012
Table 4.1 Current Development Phase and Expected Launch Year of ADCs in Clinical Development (Phase II and Higher)
Table 4.2 Adcetris: Ongoing Clinical Trials
Table 4.3 List of Some Trastuzumab Biosimilars Under Development, 2013
Table 4.4 Kadcyla / T-DM1: Ongoing Clinical Trials
Table 4.5 Inotuzumab Ozogamicin / CMC-544: Ongoing Clinical Trials
Table 4.6 Lorvotuzumab Mertansine /IMGN901: Ongoing Clinical Trials
Table 4.7 SAR3419: Ongoing Clinical Trials
Table 4.8 SAR3419: Market Estimation
Table 4.9 Comparison of Drugs Available for Metastatic Castration Resistant Prostate Cancer
Table 5.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 6.1 Companies Providing Site-Specific Conjugation Technology
Table 7.1 ImmunoGen ADC Pipeline, 2013
Table 7.2 Seattle Genetics ADC Pipeline, 2013
Table 7.3 Immunomedics ADC Pipeline, 2013
Table 8.1 SWOT Analysis of ADC Market
Table 10.1 ADCs in Clinical Development: Share (%) by Phase of Development
Table 10.2 ADCs in Clinical Development: Share (%) by Cytotoxin Used
Table 10.3 Total ADC Market (USD MM), Short-Midterm Forecast, 2012-2018 (Base Scenario)
Table 10.4 Total ADC Market (USD MM), Short-Midterm Forecast, 2012-2018 (Conservative Scenario)
Table 10.5 Total ADC Market (USD MM), Short-Midterm Forecast, 2012-2018 (Optimistic Scenario)
Table 10.6 Total ADC Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Table 10.7 Total ADC Market (USD MM), Long Term Forecast, 2019-2023 (Conservative Scenario)
Table 10.8 Total ADC Market (USD MM), Long Term Forecast, 2019-2023 (Optimistic Scenario)
Table 10.9 Adcetris Quarterly Sales, 2011-2013 (USD MM)
Table 10.10 Adcetris Market (USD MM), Short-Midterm Forecast: 2013-2018 (Base Scenario)
Table 10.11 Adcetris Market (USD MM), Short-Midterm Forecast: 2013-2018 (Conservative Scenario)
Table 10.12 Adcetris Market (USD MM), Short-Midterm Forecast: 2013-2018 (Optimistic Scenario)
Table 10.13 Adcetris Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Table 10.14 Adcetris Market (USD MM), Long Term Forecast: 2019-2023 (Conservative Scenario)
Table 10.15 Adcetris Market (USD MM), Long Term Forecast: 2019-2023 (Optimistic Scenario)
Table 10.16 Kadcyla / T-DM1 Market (USD MM), Short-Midterm Forecast: 2013-2018 (Base Scenario)
Table 10.17 Kadcyla / T-DM1 Market (USD MM), Short-Midterm Forecast: 2013-2018 (Conservative Scenario)
Table 10.18 Kadcyla / T-DM1 Market (USD MM), Short-Midterm Forecast: 2013-2018 (Optimistic Scenario)
Table 10.19 Kadcyla / T-DM1 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Table 10.20 Kadcyla / T-DM1 Market (USD MM), Long Term Forecast: 2019-2023 (Conservative Scenario)
Table 10.21 Kadcyla / T-DM1 Market (USD MM), Long Term Forecast: 2019-2023 (Optimistic Scenario)
Table 10.22 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Short-Midterm Forecast: 2015-2018 (Base Scenario)
Table 10.23 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Short-Midterm Forecast: 2015-2018 (Conservative Scenario)
Table 10.24 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Short-Midterm Forecast: 2015-2018 (Optimistic Scenario)
Table 10.25 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Table 10.26 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Conservative Scenario)
Table 10.27 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Optimistic Scenario)
Table 10.28 Glembatumumab Vedotin / CDX-011 Market (USD MM), Short-Midterm Forecast: 2016-2018 (Base Scenario)
Table 10.29 Glembatumumab Vedotin / CDX-011 Market (USD MM), Short-Midterm Forecast: 2016-2018 (Conservative Scenario)
Table 10.30 Glembatumumab Vedotin / CDX-011 Market (USD MM), Short-Midterm Forecast: 2016-2018 (Optimistic Scenario)
Table 10.31 Glembatumumab Vedotin / CDX-011 Market (USD MM), Long Term Forecast: 2016-2018 (Base Scenario)
Table 10.32 Glembatumumab Vedotin / CDX-011 Market (USD MM), Long Term Forecast: 2016-2018 (Conservative Scenario)
Table 10.33 Glembatumumab Vedotin / CDX-011 Market (USD MM), Long Term Forecast: 2016-2018 (Optimistic Scenario)
Table 10.34 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Table 10.35 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Conservative Scenario)
Table 10.36 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Optimistic Scenario)
Table 10.37 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Long Term Forecast, 2017-2018 (Base Scenario)
Table 10.38 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Long Term Forecast, 2017-2018 (Conservative Scenario)
Table 10.39 Lorvotuzumab Mertansine /IMGN901 Market (USD MM), Long Term Forecast, 2017-2018 (Optimistic Scenario)
Table 10.40 SAR3419 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Table 10.41 SAR3419 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Conservative Scenario)
Table 10.42 SAR3419 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Optimistic Scenario)
Table 10.43 SAR3419 Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Table 10.44 SAR3419 Market (USD MM), Long Term Forecast, 2019-2023 (Conservative Scenario)
Table 10.45 SAR3419 Market (USD MM), Long Term Forecast, 2019-2023 (Optimistic Scenario)
Table 10.46 BT-062 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Base Scenario)
Table 10.47 BT-062 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Conservative Scenario)
Table 10.48 BT-062 Market (USD MM), Short-Midterm Forecast, 2017-2018 (Optimistic Scenario)
Table 10.49 BT-062 Market (USD MM), Long Term Forecast, 2019-2023 (Base Scenario)
Table 10.50 BT-062 Market (USD MM), Long Term Forecast, 2019-2023 (Conservative Scenario)
Table 10.51 BT-062 Market (USD MM), Long Term Forecast, 2019-2023 (Optimistic Scenario)
Table 10.52 PSMA ADC Sales Forecast (USD MM), 2019-2023 (Base Scenario)
Table 10.53 PSMA ADC Sales Forecast (USD MM), 2019-2023 (Conservative Scenario)
Table 10.54 PSMA ADC Sales Forecast (USD MM), 2019-2023 (Optimistic Scenario)
Table 10.55 Seattle Genetics Sales Performance, 2011-2012 (USD MM)
Table 10.56 Pfizer Sales Performance, 2011-2012 (USD MM)
Table 10.57 Roche Group Sales Performance, 2011-2012 (USD MM)
Table 10.58 Roche’s HER2 Franchise Sales, 2012 and 1Q 2013 (USD MM)
The following companies have been mentioned in this report
The following organisations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES